Tag: big pharma

Moderna Creates new mRNA Vaccine

If the aftermath of the first widespread mRNA vaccine was not enough to deter the public, the government and the Centers for Disease Control and Prevention (CDC) partnered with Moderna to create a new DNA-altering vaccination for the bird flu.

And here we go again – Moderna said that their most recent vaccine is specifically for this variant (2.3.4.4b) of the flu, which has not spread from person-to-person contact. The Science Translational Medicine published Moderna’s study of the vaccine in which they exposed ferrets to the virus. Moderna won a $176 million federal funding package back in JULY to develop this vaccination.

There are only 60 known cases of this virus among humans, and nearly everyone who contracted it was exposed to infected cattle. California has already declared a state of emergency, and every politician and pharmaceutical company that enjoyed the power grab of the first pandemic is eager for the next. I cannot fathom why anyone would take this vaccine when the last mRNA vaccination FAILED. It failed to prevent the spread or transmission of the virus and injured far more people than it helped. This is why the current investigations into COVID must remain ongoing — we cannot afford a repeat of 2020.

We seriously need MAJOR political reform. Anyone who supports the absolute immunity for the Pharmaceutical Industry should be removed from office – NOW! If one in every 10,000 General Motors cars blew up when you just turned the key but has absolute immunity from lawsuits, why fix the problem? These people know that even with normal vaccines, there is also a portion of people who will die. That is just a matter of fact. That is why they bribed our politicians for absolute immunity. Why ask for that unless you were getting sued?

Keep reading

FDA Updates Recall On Blood Pressure Medication Due To Possible Carcinogen

A third blood pressure medication was recalled across the United States in the past several weeks, according to a notice updated on the U.S. Food and Drug Administration’s (FDA) website on Dec. 16.

The notice said that New Jersey-based Aurobindo Pharma USA Inc. is recalling Nebivolol tablets in 2.5 milligram doses in 30-count bottles, which are only available by prescription. Nebivolol, a type of beta blocker, is used to treat high blood pressure.

The reason for the recall is because of the “presence of nitrosamine drug substance related impurity,” adding that discovered N-nitroso nebivolol levels are above the “acceptable intake limit,” it said. N-nitroso nebivolol is a nitrosamine and is considered mutagenic.

It was first initiated by Aurobindo earlier this month. The FDA classified the recall as Class II on Dec. 16, which occurs when there is a low chance of injury or death, and a possibility of “adverse events” that may have irreversible effects. They are issued if the product can cause medically reversible or temporary health problems—or if there is a small chance of serious health consequences.

The lot numbers being recalled are: NB0224001A and NB0224001B. It has an expiration date of April 2027 and a National Drug Code, or NDC, of 59651-137-30, according to the FDA.

Nitrosamines are compounds that can increase the risk of cancer in individuals if exposed to them above levels established by the FDA, or for long periods of time, the agency says on its website.

“A person taking a drug that contains nitrosamines at-or-below the acceptable daily intake limits every day for 70 years is not expected to have an increased risk of cancer,” the FDA adds.

People who are taking medications with possible “nitrosamine impurities should not stop taking their medications” and should instead speak with a health care professional.

Nitrosamines can be found in small levels in the environment and foods, including “meat, vegetables, and dairy products,” the FDA says.

Keep reading

C19 HAS TAUGHT US DOCTORS DON’T UNDERSTAND HOW MEDICINES ARE MADE

If doctors did know how medicines are made, the SARS-CoV-2 injections would never have found their way into people’s arms.

Doctors would have shouted “Nine-months to develop and make an injection? Pull the other one, matey!”

In the world of medicines, the doctor is equivalent to the pilot of an aircraft, where passenger lives are in their hands. So it is with treating disease—patient lives are in doctors’ hands.

Could you imagine a pilot allowing his aircraft to take off, knowing it had been developed and made at least ten-times faster that ever before?

The manufacturer would need to explain in great detail what it had done differently to achieve such a miraculous outcome. Questions would be:

  • How were all the component parts designed and sourced so quicky?
  • How were manufacturing and supply contracts negotiated and signed-off so quickly?
  • How much testing were the wings, engines and other safety-critical components subjected to?
  • There are lots more, feel free to insert your own questions here…

The other thing, of course, is that the physical condition of the aircraft would undoubtedly give the game away. A wonky wing maybe, the odd bump in the fuselage, wires poking out from the cockpit?

A deathtrap for all to see…

Keep reading

Study Links Ozempic To Blindness, Adding To Growing List Of Side Effects

Diabetes patients who took Ozempic were more than twice as likely to develop an eye condition that causes vision loss than patients using a different diabetes drug, according to a new study.

The study linked semaglutide, the active ingredient in Ozempic and Wegovy — which in addition to treating diabetes are widely used to lose weight — to non-arteritic anterior ischemic optic neuropathy (NAION).

The study, published last week on a preprint server, is undergoing peer review.

NAION can result in sudden vision loss due to loss of blood flow to the optic nerve. It is a major cause of severe vision loss and blindness in adults and the second-most common form of optic nerve damage after glaucoma. There is no effective treatment for the condition.

Doctors have recommended that patients considering taking these drugs should be informed of the risk, Bloomberg reported.

While the absolute risk of the disorder remains low, the authors of the study said, they found 1.4 additional cases per 10,000 among patients who took Ozempic.

Researchers analyzed data from the national healthcare registries in Denmark and Norway, comparing the rates of NAION between people taking semaglutide (Ozempic) versus those taking SGLT-2s, an older class of drugs used to treat Type 2 diabetes.

Keep reading

Just how far does the malfeasance of the FDA extend? Clinical trials of psychiatric drugs show negative outcomes – more chemical drugs are required to treat side effects

The Reality of Psychiatric Medications

Mental health conditions are often treated with pharmaceuticals, but are these products really as “safe and effective” as public health officials, healthcare professionals and drug manufacturers claim them to be?

David Wayne, psychiatric nurse, returns to “Pediatric Perspectives” to spill the beans on the true risks associated with common medications for depression, anxiety and related diagnoses.

The information contained in this episode is for informational purposes only. No material is intended to be a substitute for professional medical advice, diagnosis or treatment.”

The interview is wide-ranging and covers treatments such as anti-psychotic and anti-depressant drugs, as well as SSRI’s and Serotonin (and impotency).

Of note are the failed clinical trials and side effects that require ever more chemical drugs that are just as bad, with their own harmful side effects.

Aaron Siri pointed out the clinical trial detail in the package inserts of vaccines such as Hep B.

It looks like the same information on bad trial outcomes applies to psychiatric drugs.

The information is in the package inserts – from (dodgy) memory – I think these details are in section 6,

There are many reports of the deteriorating mental health of Americans. These “leaves rustling in the wind” could mean that these mental health issues and other physical issues, are caused by chemicals in psychiatric drugs.

All “approved” by the FDA as “safe and effective”.

Keep reading

There is no scientific definition of vaccine in US biological product law.

Reader question:

Is there a formal definition of vaccine in law?

My reply:

There is no scientific definition of vaccine in statute or regulation.

That’s why I urged Kirk Moore to ask DOJ to provide proof that what they supplied to his office was a vaccine.

DOJ can’t provide that proof, because the proof doesn’t exist.

Congress added the term ‘vaccine’ to the biological products law in 1970 for the first time but did not define the term or direct the executive agencies to adopt or promulgate scientific definitions in regulations.

There is a financial definition of ‘vaccine’ and a definition based on the design intention, adopted by Congress in 1987.

1987/12/22 – Congress and President Reagan passed Omnibus Budget Reconciliation Act of 1987, PL 100-203, 101 Stat. 1330, including Sec. 9201, Manufacturers Excise Tax on Certain Vaccines, to establish an excise tax on vaccines ordered and purchased by US government and manufactured by private companies, to fund the Vaccine Injury Compensation Trust Fund established in 1986.

This act is the only act through which Congress has ever defined the term ‘vaccine,’ defining ‘vaccine’ as “any vaccine (A) which is listed in the table contained in [26 USC 4131(b)(1)], and (B) which is manufactured or produced in the United States or which entered into the United States for consumption, use or warehousing.”

Congress in 1987 defined vaccine in the form that now appears at 26 USC 4132a(2) — “any substance designed to be administered to a human being for the prevention of 1 or more diseases” — but has never defined the term “vaccine” in physical, chemical or pharmacological terms, and neither has the HHS-FDA.

See Dean v. HHS, No. 16–1245V, 2018 WL 3104388, at * 9 (Fed. Cl. Spec. Mstr. May 29, 2018), cited in 86 FR 6249, HHS Final Rule, National Vaccine Injury Compensation Program: Revisions to the Vaccine Injury Table, “(defining ‘‘vaccine’’ as ‘‘any substance designed to be administered to a human being for the prevention of 1 or more diseases’’) (quoting 26 U.S.C. 4132(a)(2)).”

The lack of scientific definition for vaccine was reinforced/corroborated in 2011 by the US Supreme Court in Bruesewitz v. Wyeth, when the majority opinion stated at p. 13:

“Design defects…do not merit a single mention in the [1986 National Childhood Vaccine Injury Act] or the FDA’s regulations. Indeed, the FDA has never even spelled out in regulations the criteria it uses to decide whether a vaccine is safe and effective for its intended use.”

Justice Scalia did not write, but it is also true, that FDA has never spelled out in regulations the criteria it uses to identify a product as a vaccine.

Keep reading

Big Pharma Eli Lilly Announces $3B Manufacturing Expansion in Kenosha Following Strategic Meeting with Trump and RFK Jr. at Mar-a-Lago

Kenosha, Wisconsin, is poised for an economic revival, thanks to a groundbreaking $3 billion investment from pharmaceutical giant Eli Lilly.

This announcement comes just days after a high-stakes meeting at Mar-a-Lago between President-elect Donald Trump, his nominee for Secretary of Health and Human Services Robert F. Kennedy Jr., and top executives from major pharmaceutical companies, including Eli Lilly and Pfizer.

The meeting, which also included Trump’s incoming chief of staff Susie Wiles and representatives from the Pharmaceutical Research and Manufacturers of America (PhRMA), signals a potential realignment of U.S. health policy.

While the specifics remain under wraps, insiders suggest the discussions centered on finding cures for cancer, among other topics, according to Axios.

This development is being hailed as a masterstroke by Trump, who has long championed bringing jobs back to the U.S. and revamping the pharmaceutical industry to prioritize American innovation and production.

Eli Lilly’s decision to expand its Kenosha facility is being lauded by Trump supporters as a direct result of the strategic discussions in Mar-a-Lago.

According to the company’s press release, the $3 billion investment will not only enhance the production of injectable medicines but also create 750 high-paying jobs in Kenosha County.

The expansion will also generate more than 2,000 construction jobs, making it one of the largest economic boosts in the region’s history.

Keep reading

Fascism comes to New Zealand

It’s the abuser’s Swiss army knife for the empty-headed. Multipurpose, its meaning has near-infinite elasticity. You can be labelled ‘fascist’ if you say that there are only two biological sexes, or that women should not have to undress in front of men, or that men should be excluded from women’s sports, or that men can’t get pregnant, or even if you voted for Trump.

Such is the ignorance of the 1930s and 1940s that in contemporary discourse, ‘fascist’ has lost all meaning.

Yet, in a very real sense, New Zealand is now Fascist. If this seems an extraordinary statement, consider Mussolini’s widely reported (though not documented), definition [Emphasis added]:

“Fascism should more properly be called corporatism because it is the merger of state and corporate power.”

This definition may not be to everyone’s liking, but has the virtue of simplicity and clarity. Moreover, it is an accurate description of what is happening in America, Europe, Australia and – as I shall show – New Zealand.

There can be no clearer illustration of the corporate rule of New Zealand than the stranglehold the pharmaceutical industry has on government and media.

Keep reading

Popular Asthma Drug May Cause Serious Mental Health Issues in Children and Adults, FDA Data Reveals

Singulair, a widely-prescribed asthma drug, may cause serious mental health issues, according to data revealed last week by the U.S. Food and Drug Administration (FDA). FDA researchers found that the drug, also sold under the generic label montelukast, attaches to multiple brain receptors critical to psychiatric functioning.

The data support the thousands of patients and dozens of studies that have reported harmful psychiatric side effects, including depression, suicide, anxiety and aggression.

Originally manufactured by Merck, the drug is prescribed for year-round indoor allergies in patients 6 months and up, seasonal outdoor allergies in patients 2 years and up, and for preventing asthma in patients 1 year and older.

Julia Marschallinger, Ph.D., a cell biologist who has studied the drug at the Institute of Molecular Regenerative Medicine in Austria, told Reuters the new data bolster patients’ reports of harm. “It’s definitely doing something that’s concerning,” she said.

The FDA researchers presented their findings — which are preliminary and have not yet been released publicly — during a Nov. 20 meeting of the American College of Toxicology in Austin, Texas.

Their lab tests showed “significant binding” of the drug to multiple brain receptors, according to Jessica Oliphant, Ph.D., a deputy director at FDA’s National Center for Toxicological Research.

“These data indicate that montelukast is highest in brain regions known to be involved in (psychiatric effects),” Oliphant said. The FDA researchers’ findings confirmed prior research that showed montelukast penetrates the brains of rats.

The data do not show whether the binding mechanism leads directly to harmful effects in individual patients or which patients are particularly at risk, Reuters reported.

The FDA said it has no plans to update the drug’s label based on the new data. The FDA did not immediately respond to our request for comment.

According to the Asthma and Allergy Foundation of America, about 4.9 million children under 18 have asthma, making it a leading chronic disease in children. Overall, nearly 28 million — or 1 in 12 — people in the U.S. have asthma.

Keep reading

How RFK Jr. could use levers of HHS to shape vaccine and drug outcomes

Robert F. Kennedy Jr. could use Health and Human Services’ vast bureaucracy to put a distinct stamp on vaccine policy, drug approvals and food regulation if he’s confirmed. But with so many legal requirements and bureaucratic layers baked into the process, it’s hardly a foregone conclusion he will.

Why it matters: Experts say RFK Jr.’s public calls for more transparency and vows to shore up the trustworthiness of federal health agencies may translate into more requests for vaccine safety data and into appointing like-minded individuals to advisory panels that could influence coverage of drugs, services and devices.

  • They also say it could result in shifting public health funding to chronic disease or environmental health and away from infectious disease, or a diversion of federal investment to study unproven health issues instead of known risks.
  • And they’re expecting attempts to remove job protections from career federal employees who work in policymaking roles and reduce the ranks of officials who don’t align with RFK Jr.’s goals.

Between the lines: In the near term, he’s likely to focus on how much influence he might exert on negotiations between the Food and Drug Administration and the health industries it regulates over user fees for companies, which fund a significant portion of the FDA’s operations.

  • Talks to reauthorize programs for prescription drugs, medical devices and generics are due to start next year and could provide a crucible for Trump appointees to take aim at what they describe as regulators’ coziness with industries they police.
  • The spotlight could fall especially hard on vaccines, based on Kennedy’s criticisms of the federal pandemic response, his calls to revoke emergency use authorizations for COVID shots and his advocacy of hydroxychloroquine and ivermectin, both of which were found ineffective for treating the virus.

Keep reading